Lataa...
Pioglitazone and alogliptin combination therapy in type 2 diabetes: a pathophysiologically sound treatment
Insulin resistance and islet (beta and alpha) cell dysfunction are major pathophysiologic abnormalities in type 2 diabetes mellitus (T2DM). Pioglitazone is a potent insulin sensitizer, improves pancreatic beta cell function and has been shown in several outcome trials to lower the risk of atheroscle...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Dove Medical Press
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2941781/ https://ncbi.nlm.nih.gov/pubmed/20859539 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|